Roberto Baratta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roberto Baratta has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Lucia Frittitta
Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
28 shared publications - Vincenzo Trischitta
Research Unit of Diabetes and Endocrine Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
14 shared publications - Riccardo Vigneri
Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, 95122 Catania, Italy
12 shared publications - Andrea Tumminia
Endocrine Unit, Garibaldi-Nesima Hospital, Catania, Italy
11 shared publications - Francesco Frasca
Department of Clinical and Experimental Medicine, Endocrinology Section, Garibaldi-Nesima Hospital, University of Catania, Catania, Italy
6 shared publications - Francesco Galeano
Department of Clinical and Experimental Medicine, Endocrinology Section, Garibaldi-Nesima Hospital, University of Catania, Catania, Italy
6 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 241
Optimizing the use of the Omnipod 5 system in adults with type 1 diabetes: an Italian expert Delphi consensus
- 22 September 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 241
Open AccessOptimizing the use of the Omnipod 5 system in adults with type 1 diabetes: an Italian expert Delphi consensus
- Open Access
- 10 July 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 222
The CRUMB study: closed-loop response to unannounced mixed and carbohydrates-rich breakfasts. A randomized controlled crossover pilot-study in a cohort of adolescents with type 1 diabetes
Purpose: Unannounced meals pose a major challenge to type 1 diabetes patients. This study compared the performance of two automated insulin delivery (AID) algorithms, the Medtronic MiniMed 780G’s proportional-integral-derivative (PID) and the Tandem t: slim X2’s model predictive control (MPC), following unannounced breakfasts (ClinicalTrials.gov identifier: NCT07455643, retrospectively registered the 3rd of February 2026). Methods: In a randomized crossover study, we enrolled 20 children between 11 and 18 years using the MiniMed 780G or the Tandem t: slim X2 AID system. Endpoints included 2-hour and 4-hour blood glucose difference (ΔBG), glucose peak, time to peak, and time spent above (TAR), below (TBS), in range (TIR), and in tight range (TITR). Two meals were tested: a carbohydrate (CHO) meal and a mixed one, both containing 30 g of carbohydrates, and additional 15 g proteins for the mixed meal. Announced (AM) and unannounced (UM) meals were analyzed. Results: AM, compared to UM, showed significant higher 2-hourΔBG; conversely 4-hourΔBG did not differ significantly. In CHO AM, algorithms were comparable. In mixed AM, PID gained lower peaks and TAR, with higher TIR and TITR. In UM, PID obtained lower 2-hourΔBG than MPC, with reduced peak, TAR, and improved TIR and TITR. Differences in 4-hourΔBG and time-at-peak were not significant. Conclusion: Both AID algorithms mitigated postprandial glycemia and returned glucose to baseline levels within 4 h without safety concerns. The PID demonstrated higher reactivity to unannounced meals, while performances were comparable when meal boluses were properly announced. ClinicalTrials.gov identifier: NCT07455643.
- 10 July 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 222
Open AccessThe CRUMB study: closed-loop response to unannounced mixed and carbohydrates-rich breakfasts. A randomized controlled crossover pilot-study in a cohort of adolescents with type 1 diabetes
Purpose: Unannounced meals pose a major challenge to type 1 diabetes patients. This study compared the performance of two automated insulin delivery (AID) algorithms, the Medtronic MiniMed 780G’s proportional-integral-derivative (PID) and the Tandem t: slim X2’s model predictive control (MPC), following unannounced breakfasts (ClinicalTrials.gov identifier: NCT07455643, retrospectively registered the 3rd of February 2026). Methods: In a randomized crossover study, we enrolled 20 children between 11 and 18 years using the MiniMed 780G or the Tandem t: slim X2 AID system. Endpoints included 2-hour and 4-hour blood glucose difference (ΔBG), glucose peak, time to peak, and time spent above (TAR), below (TBS), in range (TIR), and in tight range (TITR). Two meals were tested: a carbohydrate (CHO) meal and a mixed one, both containing 30 g of carbohydrates, and additional 15 g proteins for the mixed meal. Announced (AM) and unannounced (UM) meals were analyzed. Results: AM, compared to UM, showed significant higher 2-hourΔBG; conversely 4-hourΔBG did not differ significantly. In CHO AM, algorithms were comparable. In mixed AM, PID gained lower peaks and TAR, with higher TIR and TITR. In UM, PID obtained lower 2-hourΔBG than MPC, with reduced peak, TAR, and improved TIR and TITR. Differences in 4-hourΔBG and time-at-peak were not significant. Conclusion: Both AID algorithms mitigated postprandial glycemia and returned glucose to baseline levels within 4 h without safety concerns. The PID demonstrated higher reactivity to unannounced meals, while performances were comparable when meal boluses were properly announced. ClinicalTrials.gov identifier: NCT07455643.
- Open Access
- 5 June 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (7) , 1-8
Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety
Background: Recurrent weight gain after bariatric surgery (BS) or endoscopic bariatric therapy (EBT) remains a long-term clinical challenge, potentially undermining long-term treatment success. Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown promising results in obesity treatment, but data regarding its use in post BS or EBT recurrent weight gain are limited. Methods: This observational cohort study evaluated the effectiveness and safety of tirzepatide in patients with recurrent weight gain after BS or EBT. Anthropometric data, BMI categories, and adverse events were collected at baseline and after 24 weeks of treatment. Results: A total of 34 patients (26 females, 8 males) who experienced recurrent weight gain after BS ( n = 32) or EBT ( n = 2) were treated with once-weekly subcutaneous tirzepatide (dosing range 2.5–10 mg/week). After 24 weeks, the mean percentage total body weight loss (%TBWL) was 18.1 ± 5.6% ( p < 0.0001), with a significant reduction in waist circumference ( p < 0.0001). Most patients shifted to lower BMI categories, with the majority reaching overweight or normal weight status. Adverse events were exclusively gastrointestinal (constipation, diarrhea, nausea), generally mild, and did not lead to treatment discontinuation. Conclusion: Preliminary evidence suggests that tirzepatide is associated with significant weight loss and good tolerability in this observational cohort for managing recurrent weight gain after bariatric surgery and endoscopic bariatric therapy. These findings suggest a potential role for tirzepatide as a valuable nonsurgical option in the multidisciplinary management of patients experiencing recurrent weight gain after bariatric procedures.
- 5 June 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (7) , 1-8
Open AccessTirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety
Background: Recurrent weight gain after bariatric surgery (BS) or endoscopic bariatric therapy (EBT) remains a long-term clinical challenge, potentially undermining long-term treatment success. Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown promising results in obesity treatment, but data regarding its use in post BS or EBT recurrent weight gain are limited. Methods: This observational cohort study evaluated the effectiveness and safety of tirzepatide in patients with recurrent weight gain after BS or EBT. Anthropometric data, BMI categories, and adverse events were collected at baseline and after 24 weeks of treatment. Results: A total of 34 patients (26 females, 8 males) who experienced recurrent weight gain after BS ( n = 32) or EBT ( n = 2) were treated with once-weekly subcutaneous tirzepatide (dosing range 2.5–10 mg/week). After 24 weeks, the mean percentage total body weight loss (%TBWL) was 18.1 ± 5.6% ( p < 0.0001), with a significant reduction in waist circumference ( p < 0.0001). Most patients shifted to lower BMI categories, with the majority reaching overweight or normal weight status. Adverse events were exclusively gastrointestinal (constipation, diarrhea, nausea), generally mild, and did not lead to treatment discontinuation. Conclusion: Preliminary evidence suggests that tirzepatide is associated with significant weight loss and good tolerability in this observational cohort for managing recurrent weight gain after bariatric surgery and endoscopic bariatric therapy. These findings suggest a potential role for tirzepatide as a valuable nonsurgical option in the multidisciplinary management of patients experiencing recurrent weight gain after bariatric procedures.
- Open Access
- 17 March 2026
- Published by Springer Nature in Acta Diabetologica
- Vol. 63 (5) , 919-927
Type 2 diabetes mellitus is associated with asymptomatic acute abdomen among elderly patients admitted to acute tertiary care hospital wards
Background: Pain may be absent in a substantial proportion of elderly patients with acute abdominal conditions. This study explored the association between type 2 diabetes mellitus (T2DM) and asymptomatic presentation. Methods: We conducted a cross-sectional analysis of 215 patients aged ≥ 65 years admitted with acute abdominal conditions. Demographic, clinical, and laboratory data were extracted from medical records. Descriptive statistics and multivariable logistic regression were used to identify associative predictors of asymptomatic acute abdomen (AAA). Results: The median age was 82 years [77–86]; 54.4% ( n = 117) were female; 31.2% ( n = 67) had T2DM. Overall, 33.5% ( n = 72) presented without abdominal pain. T2DM prevalence was higher in AAA than symptomatic patients (44.4% vs. 24.5%, p < 0.01). In multivariable analysis, T2DM (OR 1.95, 95% CI 1.10–3.45, p = 0.02), lower heart rate (OR 0.83, 95% CI 0.71–0.96, p = 0.01), and absence of fever (OR 0.50, 95% CI 0.26–0.95, p = 0.03) were associated with AAA. Among patients with T2DM, longer diabetes duration (12.5 years [10.5–14.5] vs. 8.8 years [5.0–11.0]; p < 0.01) and higher HbA1c (8.2% [7.2–8.7] vs. 7.5% [6.8–7.6]; p = 0.02) were associated with asymptomatic presentation. Conclusions: Asymptomatic acute abdomen is common among elderly patients. Long-standing and poorly controlled T2DM is associated with absent pain. Prospective studies are needed to clarify causal mechanisms, and early glyco-metabolic assessment may aid recognition of at-risk patients.
- 17 March 2026
- Published by Springer Nature in Acta Diabetologica
- Vol. 63 (5) , 919-927
Open AccessType 2 diabetes mellitus is associated with asymptomatic acute abdomen among elderly patients admitted to acute tertiary care hospital wards
Background: Pain may be absent in a substantial proportion of elderly patients with acute abdominal conditions. This study explored the association between type 2 diabetes mellitus (T2DM) and asymptomatic presentation. Methods: We conducted a cross-sectional analysis of 215 patients aged ≥ 65 years admitted with acute abdominal conditions. Demographic, clinical, and laboratory data were extracted from medical records. Descriptive statistics and multivariable logistic regression were used to identify associative predictors of asymptomatic acute abdomen (AAA). Results: The median age was 82 years [77–86]; 54.4% ( n = 117) were female; 31.2% ( n = 67) had T2DM. Overall, 33.5% ( n = 72) presented without abdominal pain. T2DM prevalence was higher in AAA than symptomatic patients (44.4% vs. 24.5%, p < 0.01). In multivariable analysis, T2DM (OR 1.95, 95% CI 1.10–3.45, p = 0.02), lower heart rate (OR 0.83, 95% CI 0.71–0.96, p = 0.01), and absence of fever (OR 0.50, 95% CI 0.26–0.95, p = 0.03) were associated with AAA. Among patients with T2DM, longer diabetes duration (12.5 years [10.5–14.5] vs. 8.8 years [5.0–11.0]; p < 0.01) and higher HbA1c (8.2% [7.2–8.7] vs. 7.5% [6.8–7.6]; p = 0.02) were associated with asymptomatic presentation. Conclusions: Asymptomatic acute abdomen is common among elderly patients. Long-standing and poorly controlled T2DM is associated with absent pain. Prospective studies are needed to clarify causal mechanisms, and early glyco-metabolic assessment may aid recognition of at-risk patients.
- Open Access
- 10 April 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 224, 112173
The automated correction index (ACI), a novel report-derived metric correlated to glucose control and variability in patients with type 1 diabetes on advanced hybrid closed loop therapy
- 10 April 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 224, 112173
Open AccessThe automated correction index (ACI), a novel report-derived metric correlated to glucose control and variability in patients with type 1 diabetes on advanced hybrid closed loop therapy
- Open Access
Clinical Assessment of Altered Eating Behaviors in People with Obesity Using the EBA-O Questionnaire
Background/Objectives: Over the past decade, numerous studies have explored the bidirectional relationship between obesity and mental health, mainly eating disorders (EDs). This study aimed to assess the prevalence and characteristics of altered eating behaviors (AEBs) in a cohort of people with obesity (PwO) using the validated Eating Behaviors Assessment for Obesity (EBA-O). Methods: We conducted a cross-sectional study from May 2023 to April 2024, recruiting consecutive PwO seeking weight loss. Participants completed the 18-item EBA-O questionnaire, which focuses on five primary eating behaviors: night eating, food addiction, sweet eating, hyperphagia, and binge eating. Unlike other validated tools, the EBA-O is specifically designed to capture these behaviors in PwO and is easy for patients to self-administer. We also collected sociodemographic and clinical data. Results: A total of 127 participants were included (76 women, median age 52 years, median BMI 42.9 kg/m2). We found a significant prevalence of AEBs: 33.1% for sweet eating, 23.6% for hyperphagia, 15.7% for food addiction, 14.2% for binge eating, and 7.1% for night eating. The EBA-O scores correlated positively with BMI (r = 0.201, p = 0.024) and increased across BMI categories (p = 0.001). Males had higher scores for night eating and hyperphagia (p = 0.01), and active smokers had higher hyperphagia scores (p = 0.043) than ex-smokers and non-smokers. The night eating scores were inversely correlated with sleep hours (r = −0.197, p = 0.026), and food addiction was positively correlated with age (r = 0.261, p = 0.003); conversely, hyperphagia (r = −0.198, p = 0.025) and binge eating (r = −0.229, p = 0.010) were inversely correlated with age. PwO without diabetes had higher scores for food addiction (p = 0.01) and binge eating (p = 0.004) compared to those with diabetes. Conclusions: These results highlight the potential to characterize PwO based on their AEBs, offering new opportunities to tailor treatment strategies for PwO by targeting specific eating behaviors.
Open AccessClinical Assessment of Altered Eating Behaviors in People with Obesity Using the EBA-O Questionnaire
Background/Objectives: Over the past decade, numerous studies have explored the bidirectional relationship between obesity and mental health, mainly eating disorders (EDs). This study aimed to assess the prevalence and characteristics of altered eating behaviors (AEBs) in a cohort of people with obesity (PwO) using the validated Eating Behaviors Assessment for Obesity (EBA-O). Methods: We conducted a cross-sectional study from May 2023 to April 2024, recruiting consecutive PwO seeking weight loss. Participants completed the 18-item EBA-O questionnaire, which focuses on five primary eating behaviors: night eating, food addiction, sweet eating, hyperphagia, and binge eating. Unlike other validated tools, the EBA-O is specifically designed to capture these behaviors in PwO and is easy for patients to self-administer. We also collected sociodemographic and clinical data. Results: A total of 127 participants were included (76 women, median age 52 years, median BMI 42.9 kg/m2). We found a significant prevalence of AEBs: 33.1% for sweet eating, 23.6% for hyperphagia, 15.7% for food addiction, 14.2% for binge eating, and 7.1% for night eating. The EBA-O scores correlated positively with BMI (r = 0.201, p = 0.024) and increased across BMI categories (p = 0.001). Males had higher scores for night eating and hyperphagia (p = 0.01), and active smokers had higher hyperphagia scores (p = 0.043) than ex-smokers and non-smokers. The night eating scores were inversely correlated with sleep hours (r = −0.197, p = 0.026), and food addiction was positively correlated with age (r = 0.261, p = 0.003); conversely, hyperphagia (r = −0.198, p = 0.025) and binge eating (r = −0.229, p = 0.010) were inversely correlated with age. PwO without diabetes had higher scores for food addiction (p = 0.01) and binge eating (p = 0.004) compared to those with diabetes. Conclusions: These results highlight the potential to characterize PwO based on their AEBs, offering new opportunities to tailor treatment strategies for PwO by targeting specific eating behaviors.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2025 (1) , 8841993
Severe Late‐Onset Abiraterone‐Induced Hypokalemia in a Diabetic Patient With Concomitant Adrenal Gland Incidentaloma: A Diagnostic Challenge
Prostate cancer is the most prevalent cancer among men in Western countries and is commonly managed by androgen deprivation therapy for locally advanced or metastatic stages. Even if initially effective, most patients eventually develop resistance to this treatment. Approved in 2011 for castration‐resistant prostate cancer, abiraterone acetate inhibits the CYP17A1 enzyme, which is crucial in androgen and cortisol synthesis. This inhibition disrupts feedback on adrenocorticotropic hormone (ACTH), causing mineralocorticoid excess syndrome (MES), which is characterized by fluid retention, hypokalemia, and hypertension. MES can persist even with glucocorticoid supplementation, as observed in some cases. This study describes the case of a 68‐year‐old male with prostate cancer who developed severe, treatment‐resistant hypokalemia after 6 years of abiraterone and prednisone therapy. The patient presented with poorly controlled diabetes and notable hypokalemia despite oral and parenteral potassium supplementation. Imaging revealed an adrenal adenoma; however, low renin and aldosterone levels suggested that abiraterone‐induced MES, rather than primary aldosteronism, was responsible for his hypokalemia. The main therapy adjustment consisted of switching prednisone to dexamethasone to enhance ACTH suppression, effectively resolving the patient’s hypokalemia. This case underscores the need for MES monitoring in patients on abiraterone, as MES can develop or worsen over time. Physicians should consider dexamethasone over prednisone in persistent MES cases, always monitoring also for the risk of developing Cushing syndrome. Given the rising prostate cancer incidence, clinicians must remain vigilant for MES‐related complications with abiraterone, including delayed‐onset severe hypokalemia.
- 1 January 2025
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2025 (1) , 8841993
Open AccessSevere Late‐Onset Abiraterone‐Induced Hypokalemia in a Diabetic Patient With Concomitant Adrenal Gland Incidentaloma: A Diagnostic Challenge
Prostate cancer is the most prevalent cancer among men in Western countries and is commonly managed by androgen deprivation therapy for locally advanced or metastatic stages. Even if initially effective, most patients eventually develop resistance to this treatment. Approved in 2011 for castration‐resistant prostate cancer, abiraterone acetate inhibits the CYP17A1 enzyme, which is crucial in androgen and cortisol synthesis. This inhibition disrupts feedback on adrenocorticotropic hormone (ACTH), causing mineralocorticoid excess syndrome (MES), which is characterized by fluid retention, hypokalemia, and hypertension. MES can persist even with glucocorticoid supplementation, as observed in some cases. This study describes the case of a 68‐year‐old male with prostate cancer who developed severe, treatment‐resistant hypokalemia after 6 years of abiraterone and prednisone therapy. The patient presented with poorly controlled diabetes and notable hypokalemia despite oral and parenteral potassium supplementation. Imaging revealed an adrenal adenoma; however, low renin and aldosterone levels suggested that abiraterone‐induced MES, rather than primary aldosteronism, was responsible for his hypokalemia. The main therapy adjustment consisted of switching prednisone to dexamethasone to enhance ACTH suppression, effectively resolving the patient’s hypokalemia. This case underscores the need for MES monitoring in patients on abiraterone, as MES can develop or worsen over time. Physicians should consider dexamethasone over prednisone in persistent MES cases, always monitoring also for the risk of developing Cushing syndrome. Given the rising prostate cancer incidence, clinicians must remain vigilant for MES‐related complications with abiraterone, including delayed‐onset severe hypokalemia.
- Open Access
Influence of Mediterranean Diet on Sexual Function in People with Metabolic Syndrome: A Narrative Review
Metabolic syndrome (MS), a cluster of cardiometabolic disorders, and sexual dysfunction are two conditions that impact a large proportion of the general population. Although they can occur independently, they are frequently linked and significantly affect people’s quality of life. In recent years, research has increasingly focused on the importance of diet, particularly the Mediterranean diet (MD), in modulating sexual function due to its anti-inflammatory, antioxidant, and vasodilatory properties. In this narrative review, we examined the relationship between MS and sexual function in both men and women, with a special emphasis on the MD’s therapeutic efficacy in improving sexual dysfunction. In men, MD has been shown to ameliorate erectile dysfunction, as well as several sperm parameters, perhaps leading to improved fertility. On the other hand, adherence to MD has been demonstrated to partially recover several sexual dysfunctions in women, such as those related to their menstrual cycle, menopause, endometriosis, and polycystic ovary syndrome. These favorable effects of MD have been demonstrated in both sexes also among people affected by MS. However, more targeted studies are needed to validate these data for different dietary approaches as well.
Open AccessInfluence of Mediterranean Diet on Sexual Function in People with Metabolic Syndrome: A Narrative Review
Metabolic syndrome (MS), a cluster of cardiometabolic disorders, and sexual dysfunction are two conditions that impact a large proportion of the general population. Although they can occur independently, they are frequently linked and significantly affect people’s quality of life. In recent years, research has increasingly focused on the importance of diet, particularly the Mediterranean diet (MD), in modulating sexual function due to its anti-inflammatory, antioxidant, and vasodilatory properties. In this narrative review, we examined the relationship between MS and sexual function in both men and women, with a special emphasis on the MD’s therapeutic efficacy in improving sexual dysfunction. In men, MD has been shown to ameliorate erectile dysfunction, as well as several sperm parameters, perhaps leading to improved fertility. On the other hand, adherence to MD has been demonstrated to partially recover several sexual dysfunctions in women, such as those related to their menstrual cycle, menopause, endometriosis, and polycystic ovary syndrome. These favorable effects of MD have been demonstrated in both sexes also among people affected by MS. However, more targeted studies are needed to validate these data for different dietary approaches as well.
- Open Access
- 29 October 2023
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (3) , 763-770
Excessive generalized and visceral adiposity is associated with a higher prevalence of diabetic retinopathy in Caucasian patients with type 2 diabetes
- 29 October 2023
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (3) , 763-770
Open AccessExcessive generalized and visceral adiposity is associated with a higher prevalence of diabetic retinopathy in Caucasian patients with type 2 diabetes